Growing Organs for Transplant: Current Stage of the Technology

Every year, tens of thousands of people die waiting for a donor organ. According to the World Health Organization, demand for transplantable organs exceeds supply by a factor of 10 to 15. Growing organs for transplantation is one of the most promising medical technologies of the 21st century — but where exactly does it stand in 2025, somewhere between laboratory experiment and clinical practice?

The answer differs dramatically depending on which organ and which technology you're talking about. A bladder grown from a patient's own cells was successfully transplanted back in 2006. A heart bioprinted from human cells still cannot function outside the lab for more than a few seconds. Between these two points lies an entire spectrum of technologies at very different stages of maturity.

Three Core Technologies: What Makes Each Different

When researchers talk about "growing organs," they mean three fundamentally different approaches, each with its own capabilities and limitations.

Scaffold-based tissue engineering is the oldest approach. A donor organ is stripped of all its cells — a process called decellularization — leaving behind an extracellular matrix, a three-dimensional collagen framework. The patient's own cells are then seeded onto this scaffold. This is how surgeon Paolo Macchiarini grew a trachea in 2008 and transplanted it into a 30-year-old woman in London. Since the organ was built from her own cells, there was no immune rejection.

3D bioprinting deposits "bioinks" — living cells suspended in hydrogel — layer by layer to build tissue structures without a donor scaffold. Israeli company Collplant produced a rabbit-sized heart from human cells in 2019. But printing a structure is not the same as making it function: bioprinted constructs currently lack a working vascular network and cannot withstand physiological pressures.

Organoids are miniature three-dimensional tissue structures self-organized from stem cells that resemble a real organ. Kidney, intestinal, brain, and liver organoids are already used in labs to test drugs — replacing some animal trials. For transplantation, they are not yet viable: they are too small and too functionally incomplete compared to real organs.

What Has Actually Been Transplanted Into Humans

The list of lab-grown or bioengineered tissues and organs successfully transplanted into living humans is shorter than popular coverage suggests — but it does exist.

The pattern is consistent: the simpler the tissue structure and the less it depends on its own vascular supply, the further along the technology is. Skin, cartilage, and vessel grafts are thin or tubular structures that can survive on diffusion alone. A heart, kidney, or liver — complex three-dimensional organs with intricate vascular networks — is where progress stalls.

Xenotransplantation: From Pig to Human

Running parallel to bioprinting is xenotransplantation — using organs from genetically modified animals compatible enough for human recipients. Between 2022 and 2024, several breakthrough cases, all ultimately tragic, reshaped the field.

In January 2022, surgeon Bartley Griffith transplanted the heart of a genetically modified pig into 57-year-old David Bennett. The patient lived for 60 days with the pig heart — longer than any previous xenotransplant recipient. In November 2023, a pig kidney functioned in a living patient for 32 days, a record for kidney xenotransplantation. In March 2024, surgeons at Massachusetts General Hospital transplanted a pig kidney into a brain-dead patient; the organ showed no rejection for 32 days.

The U.S. FDA approved an accelerated pathway for xenotransplantation clinical trials in 2024. United Therapeutics, a company leading pig organ research, projects the first regular pig lung and kidney transplants into human patients by 2030.

The Core Barrier: Vascularization

Ask any tissue engineer what is slowing progress the most and the answer is almost always the same: vascularization — building a functional blood vessel network inside a grown organ.

Living cells cannot survive without oxygen and nutrients beyond roughly 200 to 400 micrometers from the nearest blood vessel. Skin and cartilage are thin enough for diffusion to handle. A kidney several centimeters thick, containing millions of nephrons, requires a branching capillary network — and no bioprinter today can reproduce that architecture in a functioning state.

A team from UCSF and Cedars-Sinai published research in December 2024 describing a new hydrogel that prompts organoids to form vessel-like structures. It is a meaningful step — but the distance between "vessel-like structures" and a capillary network capable of sustaining blood flow under physiological pressure remains enormous.

The second major barrier is immunogenicity. Even when an organ is built from the patient's own cells, its structural components — scaffold materials, hydrogels, polymer supports — can trigger immune reactions. Xenotransplants require complex immunosuppressive regimens, and chronic rejection remains an unsolved problem.

Heart, Kidneys, Liver: Realistic Timelines

Research groups worldwide offer cautious but specific projections.

Kidney is the most realistic candidate for the first functional bioengineered transplant among complex organs. Its structure is well mapped, and organoid technology has advanced furthest for kidney tissue. Most research groups estimate the first clinical trials of partially bioengineered kidneys could happen between 2030 and 2035.

Liver shows most promise not as a full replacement but as a bridge therapy. Bioengineered mini-livers from organoids are being tested as temporary "bioreactors" during acute liver failure — keeping patients alive while an organ recovers or a donor is found. A full liver replacement is a 2040+ horizon.

Heart is the most demanding organ because it must work immediately and continuously under high mechanical load. Research teams in Israel, the United States, and Germany are pursuing bioprinted hearts from patient cells. The realistic horizon for a fully functional bioprinted heart fit for transplantation is 2040 to 2050, according to most expert consensus.

Who Is Funding Organ Engineering Research

Global investment in tissue engineering and organ bioprinting reached approximately $14 billion in 2024, according to Grand View Research, with projections of $40+ billion by 2030.

Key players include Organogenesis, United Therapeutics, Humacyte, and 3D Systems in the bioprinting space. On the public side, DARPA funds the organ-on-a-chip program in the United States, while NIH provides substantial grants targeting vascularization — the field's central bottleneck.

The organ-on-a-chip concept deserves a separate mention: microfluidic devices the size of a USB drive that mimic the functions of a human organ. These are already used by pharmaceutical companies to test drug toxicity, replacing some animal trials. They are not transplants, but they represent the first generation of working functional organ models outside the body — and the engineering insights they generate feed directly into organ-growing research.